Mineralys Therapeutics, Inc. 4

Chief Medical Officer David Malcom Rodman exercised 2,170 stock options for Mineralys Therapeutics, Inc. Common Stock and immediately sold 2,170 shares at $27.09 per share under a Rule 10b5-1 plan.

On August 10, 2026, Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised 2,170 stock options to acquire 2,170 shares of Common Stock at an exercise price of $0 per share and, pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025, immediately sold the same 2,170 shares at an average price of $27.09 per share for proceeds of approximately $58,995. After these transactions, his direct ownership decreased from 53,554 shares to 51,384 shares of Common Stock, while the underlying option position for 2,170 shares was reduced to zero as those options were fully exercised, and his remaining equity stake (51,384 shares) is worth roughly $1.39 million based on the reported sale price.

Filing Facts

CIK

1933414

Ticker

MLYS

Form

4

Source Type

fda

Accession

0001933414-26-000118

Alert Tier

5